Core Viewpoint - The company has completed a share reduction plan by its controlling shareholder, is advancing a collaboration agreement with Chr. Hansen, and is expanding its pet health business while accelerating its international strategy [1]. Share Reduction Plan - On February 2, 2026, the company announced that its controlling shareholder, Yirui Venture Capital, and its concerted parties completed a share reduction plan, reducing a total of 10.68 million shares, accounting for 2.64% of the total share capital. The reduction was conducted through centralized bidding and block trading, with a price range of 8.81 to 9.85 yuan per share. The company stated that the reduction would not affect control or operational stability, and the plan has reached its deadline [2]. Share Pledge Changes - On the same day, the actual controller, Zhu Hai, released a pledge of 4.4 million shares (accounting for 7.31% of his holdings) and re-pledged the same number of shares for personal funding needs. The announcement indicated that the pledge risk is controllable, with no risk of forced liquidation [3]. Contract Progress - A significant cooperation agreement signed with global biotechnology company Chr. Hansen in April 2025 became effective on June 16, 2025, with a term from 2025 to 2029 and a total sales target of approximately 73.06 million euros (about 600 million yuan). The company reported that the collaboration is progressing smoothly and will support overseas business expansion [4]. Business Development - The company plans to extend its reach into high-potential areas such as pet geriatric disease prevention and pet vaccines, with related business currently in the strategic layout phase. The company will announce timely updates if it meets disclosure standards [5]. Performance Strategy - The financial report for the first three quarters of 2025 shows that the company achieved an operating income of 186 million yuan (a year-on-year increase of 17.45%) and a net profit attributable to shareholders of 18 million yuan (a significant year-on-year increase of 362.49%). International business expansion has become a key focus, with the company accelerating its international layout through global cooperation [6].

| 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2026-006 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 二、备查文件 陈智英女士的书面辞职报告。 特此公告。 深圳市易瑞生物技术股份有限公司 董事会 2026 年 2 月 3 日 关于副总经理辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、高级管理人员辞职情况 深圳市易瑞生物技术股份有限公司（以下简称"公司"）董事会于近日收到 公司副总经理陈智英女士的书面辞职报告，陈智英女士因个人原因申请辞去公司 副总经理职务，原定任期为自任职生效之日起至第三届董事会届满之日止，其辞 职后不再担任公司任何职务。陈智英女士已按照公司相关管理规定进行了工作交 接。根据《公司法》《公司章程》等有关规定，陈智英女士的辞职报告自送达董 事会之日起生效。 截至本公告披露日，陈智英女士及其直系亲属未直接或间接持有公司股份， 不存在应履行而未履行的承诺事项。公司董事会对陈智英女士为公司所做出的贡 献表示衷心的感谢！ ...

Core Viewpoint - The announcement details the share reduction plan of the controlling shareholder and its concerted actions, indicating a significant divestment of shares from the company. Group 1: Share Reduction Plan - The controlling shareholder, EasyRui (Hainan) Venture Capital Co., Ltd. (EasyRui Venture), plans to reduce its holdings by up to 11,521,758 shares, representing 2.84% of the total share capital [1] - The shareholder EasyDaiRui plans to reduce its holdings by up to 288,500 shares, representing 0.07% of the total share capital [1] - The shareholder EasyKaiRui plans to reduce its holdings by up to 341,800 shares, representing 0.08% of the total share capital [2] Group 2: Reduction Results - From November 12, 2025, to January 29, 2026, the total shares reduced by the controlling shareholder and its concerted actions amounted to 10,680,200 shares, which is 2.6366% of the total share capital [2] - The average reduction price ranged from 8.81 yuan/share to 9.85 yuan/share [2] - The total cash generated from this reduction is approximately 99 million yuan [3] Group 3: Previous Reductions - EasyRui Venture and the actual controller Zhu Hai previously reduced their holdings from July 28 to September 5, 2025, with a total amount of 1.25 billion yuan [4] - The reductions included various transactions, with average prices of 10.66 yuan/share and 12.96 yuan/share for different periods [4]

Core Viewpoint - The company, Easybio, announced that its actual controller, Mr. Zhu Hai, has notified the company about the release and re-pledging of a portion of his shares [1] Group 1 - The number of shares released from pledge is 4,400,000 shares [1] - The number of shares pledged is also 4,400,000 shares [1]

Core Viewpoint - The major shareholders of Yirui Biotechnology, including Yirui Venture Capital and its affiliates, have completed a share reduction, selling a total of 10.68 million shares, which represents 2.6366% of the total share capital [1] Share Reduction Details - Yirui Venture Capital reduced its holdings by 3.82 million shares through centralized bidding at an average price of 9.85 yuan per share and 6.23 million shares through block trading at an average price of 8.81 yuan per share [1] - Yidazhi reduced its holdings by 38,400 shares through centralized bidding at an average price of 9.85 yuan per share and 250,000 shares through block trading at an average price of 9.76 yuan per share [1] - Yikaire reduced its holdings by 91,800 shares through centralized bidding at an average price of 9.85 yuan per share and 25,000 shares through block trading at an average price of 9.76 yuan per share [1] Post-Reduction Shareholding Structure - After the reduction, Yirui Venture Capital holds 122 million shares, accounting for 30.1973% of the total shares [1] - Yidazhi holds 18.7196 million shares, accounting for 4.6213% of the total shares [1] - Yikaire holds 22.2354 million shares, accounting for 5.4893% of the total shares [1] - The combined holdings of the three parties amount to 223 million shares, representing 55.1625% of the total shares [1]

Core Viewpoint - The major shareholders of EasyBio have completed their share reduction plan, selling a total of 10,680,200 shares, which represents 2.64% of the company's total share capital [1] Group 1 - EasyBio's controlling shareholder, EasyBio (Hainan) Venture Capital Co., Ltd., along with its concerted parties, has executed a share reduction plan [1] - The share reduction was conducted through centralized bidding and block trading methods [1] - As of January 30, 2026, the total shares reduced amounted to 10,680,200, out of a total share capital of 405,068,764 shares [1]

| 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2026-004 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 关于实际控制人部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市易瑞生物技术股份有限公司（以下简称"公司"）近日收到公司实 际控制人朱海先生的通知，获悉朱海先生将其持有公司的部分股份办理了解除 质押及再质押业务，现将具体内容公告如下： | | 是否为控股股 东或第一大股 | 本次解除 质押股份 | 占其所 持股份 | 占公司 总股本 | 质押起始 | 解除质押 日 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 东及其一致行 | 数量 | 比例 | 比例 | 日 | | | | | 动人 | （股） | | | | | | | | 是 | 4,400,000 | 7.31% | 1.09% | 2025年1月 24日 | 2 ...

| 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2026-005 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 关于控股股东及其一致行动人减持计划期限届满 暨减持结果的公告 公司控股股东及其一致行动人保证向本公司提供的信息内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 深圳市易瑞生物技术股份有限公司（以下简称"公司"或"本公司"）于 2025 年 10 月 13 日披露了《关于控股股东及其一致行动人减持股份的预披露公 告》（公告编号：2025-069），控股股东易瑞（海南）创业投资有限公司（以下 简称"易瑞创投"）及其一致行动人深圳易达瑞管理咨询合伙企业（有限合伙） （以下简称"易达瑞"）和深圳易凯瑞管理咨询合伙企业（有限合伙）（以下简 称"易凯瑞"）计划于上述公告披露之日起 15 个交易日后的 3 个月内以集中竞 价或大宗交易方式减持公司股份，具体情况如下： 1、持有公司股份 132,369,971 股（占公司总股本1比 ...

Group 1: Nipah Virus Outbreak in India - The recent Nipah virus outbreak in West Bengal, India, has led to 5 confirmed cases, including healthcare workers [1] - Nipah virus is a zoonotic virus that can be transmitted from infected animals to humans, with symptoms including acute respiratory infection and fatal encephalitis [1] Group 2: Company Responses and Developments - Wanfu Bio has launched various Nipah virus nucleic acid test kits, adaptable to their U-CardDx 200 platform and other PCR systems, to meet screening and detection needs [1] - Shengxiang Bio has developed a Nipah virus nucleic acid test kit based on fluorescence PCR technology, with CE certification and a focus on rapid response to public health events [2] - Capbio emphasizes the importance of their Nipah virus test kit for global quarantine and disease control efforts, highlighting its precise detection capabilities [2] - Zhijiang Bio's Nipah virus PCR test kit offers higher sensitivity and accuracy, aiming to shorten the diagnosis window [2] - Da'an Gene has created a Nipah virus nucleic acid test kit with a sensitivity of 200 copies/mL, reducing the risk of false negatives [2] Group 3: Research on Treatment - Research teams from the Wuhan Institute of Virology and Shanghai Institute of Materia Medica have confirmed that the oral nucleoside drug VV116 shows significant antiviral activity against Nipah virus [3] Group 4: Clarifications from Companies - Hualan Biological has clarified that it does not have any products related to Nipah virus, focusing instead on human vaccine manufacturing for influenza [4] - Companies such as Jindike, Yirui Bio, and Renhe Pharmaceutical have publicly stated they do not have any Nipah virus-related products [4]

Group 1 - The Nipah virus outbreak in India has led to increased attention on related concept stocks, with several companies responding urgently to the situation [1] - Companies such as Capbio and Daan Gene have reported significant stock price increases, with Capbio rising by 20% and Daan Gene by 9.99% as of January 27 [2] - Various A-share listed companies are disclosing their technology and product layouts related to Nipah virus testing, including Wanfu Bio and Shengxiang Bio, which have developed specific testing kits [3][4] Group 2 - Capbio has developed a Nipah virus nucleic acid testing kit using fluorescence PCR technology, providing essential support for global quarantine and disease control monitoring [4] - Wanfu Bio has launched different product forms of the Nipah virus nucleic acid testing kit, compatible with its molecular POCT platform and other PCR systems [3] - Some companies, such as Hualan Biological and others, have clarified that they do not have any business related to Nipah virus vaccines or products [5][6]